

# An atlas of active enhancers across human cell types and tissues

Robin Andersson<sup>1\*</sup>, Claudia Gebhard<sup>2,3\*</sup>, Irene Miguel-Escalada<sup>4</sup>, Ilka Hoof<sup>1</sup>, Jette Bornholdt<sup>1</sup>, Mette Boyd<sup>1</sup>, Yun Chen<sup>1</sup>, Xiaobei Zhao<sup>1,5</sup>, Christian Schmidl<sup>2</sup>, Takahiro Suzuki<sup>6,7</sup>, Evgenia Ntini<sup>8</sup>, Erik Arner<sup>6,7</sup>, Eivind Valen<sup>1,9</sup>, Kang Li<sup>1</sup>, Lucia Schwarzfischer<sup>2</sup>, Dagmar Glatz<sup>2</sup>, Johanna Raithe<sup>2</sup>, Berit Lilje<sup>1</sup>, Nicolas Rapin<sup>1,10</sup>, Frederik Otzen Bagger<sup>1,10</sup>, Mette Jørgensen<sup>1</sup>, Peter Refsing Andersen<sup>8</sup>, Nicolas Bertin<sup>6,7</sup>, Owen Rackham<sup>6,7</sup>, A. Maxwell Burroughs<sup>6,7</sup>, J. Kenneth Baillie<sup>11</sup>, Yuri Ishizu<sup>6,7</sup>, Yuri Shimizu<sup>6,7</sup>, Erina Furuhashi<sup>6,7</sup>, Shiori Maeda<sup>6,7</sup>, Yutaka Negishi<sup>6,7</sup>, Christopher J. Mungall<sup>12</sup>, Terrence F. Meehan<sup>13</sup>, Timo Lassmann<sup>6,7</sup>, Masayoshi Itoh<sup>6,7,14</sup>, Hideya Kawaji<sup>6,14</sup>, Naoto Kondo<sup>6,14</sup>, Jun Kawai<sup>6,14</sup>, Andreas Lennartsson<sup>15</sup>, Carsten O. Daub<sup>6,7,15</sup>, Peter Heutink<sup>16</sup>, David A. Hume<sup>11</sup>, Torben Heick Jensen<sup>8</sup>, Harukazu Suzuki<sup>6,7</sup>, Yoshihide Hayashizaki<sup>6,14</sup>, Ferenc Müller<sup>4</sup>, The FANTOM Consortium†, Alistair R. R. Forrest<sup>6,7</sup>, Piero Carninci<sup>6,7</sup>, Michael Rehli<sup>2,3</sup> & Albin Sandelin<sup>1</sup>

**Enhancers control the correct temporal and cell-type-specific activation of gene expression in multicellular eukaryotes. Knowing their properties, regulatory activity and targets is crucial to understand the regulation of differentiation and homeostasis. Here we use the FANTOM5 panel of samples, covering the majority of human tissues and cell types, to produce an atlas of active, *in vivo*-transcribed enhancers. We show that enhancers share properties with CpG-poor messenger RNA promoters but produce bidirectional, exosome-sensitive, relatively short unspliced RNAs, the generation of which is strongly related to enhancer activity. The atlas is used to compare regulatory programs between different cells at unprecedented depth, to identify disease-associated regulatory single nucleotide polymorphisms, and to classify cell-type-specific and ubiquitous enhancers. We further explore the utility of enhancer redundancy, which explains gene expression strength rather than expression patterns. The online FANTOM5 enhancer atlas represents a unique resource for studies on cell-type-specific enhancers and gene regulation.**

Precise regulation of gene expression in time and space is required for development, differentiation and homeostasis<sup>1</sup>. Sequence elements within or near core promoter regions contribute to regulation<sup>2</sup>, but promoter-distal regulatory regions like enhancers are essential in the control of cell-type specificity<sup>1</sup>. Enhancers were originally defined as remote elements that increase transcription independently of their orientation, position and distance to a promoter<sup>3</sup>. They were only recently found to initiate RNA polymerase II (RNAPII) transcription, producing so-called eRNAs<sup>4</sup>. Genomic locations of enhancers can be detected by mapping of chromatin marks and transcription factor binding sites from chromatin immunoprecipitation (ChIP) assays and DNase I hypersensitive sites (DHSs) (reviewed in ref. 1), but there has been no systematic analysis of enhancer usage in the large variety of cell types and tissues present in the human body.

Using cap analysis of gene expression<sup>5</sup> (CAGE), we show that enhancer activity can be detected through the presence of balanced bidirectional capped transcripts, enabling the identification of enhancers from small primary cell populations. Based upon the FANTOM5 CAGE expression atlas encompassing 432 primary cell, 135 tissue and 241 cell line

samples from human<sup>6</sup>, we identify 43,011 enhancer candidates and characterize their activity across the majority of human cell types and tissues. The resulting catalogue of transcribed enhancers enables classification of ubiquitous and cell-type-specific enhancers, modelling of physical interactions between multiple enhancers and TSSs, and identification of potential disease-associated regulatory single nucleotide polymorphisms (SNPs).


## Bidirectional capped RNAs identify active enhancers

The FANTOM5 project has generated a CAGE-based transcription start site (TSS) atlas across a broad panel of primary cells, tissues and cell lines covering the vast majority of human cell types<sup>6</sup>. Within that data set, well-studied enhancers often have CAGE peaks delineating nucleosome-deficient regions (NDRs) (Supplementary Fig. 1). To determine whether this is a general enhancer feature, FANTOM5 CAGE (Supplementary Table 1) was superimposed on active (H3K27ac-marked) enhancers defined by HeLa-S3 ENCODE ChIP-seq data<sup>7</sup>. CAGE tags showed a bimodal distribution flanking the central P300 peak, with divergent transcription from the enhancer (Fig. 1a). Similar patterns

<sup>1</sup>The Bioinformatics Centre, Department of Biology & Biotech Research and Innovation Centre, University of Copenhagen, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark. <sup>2</sup>Department of Internal Medicine III, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany. <sup>3</sup>Regensburg Centre for Interventional Immunology (RCI), D-93042 Regensburg, Germany. <sup>4</sup>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. <sup>5</sup>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA. <sup>6</sup>RIKEN OMICS Science Centre, RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa 230-0045, Japan. <sup>7</sup>RIKEN Center for Life Science Technologies (Division of Genomic Technologies), RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa 230-0045, Japan. <sup>8</sup>Centre for mRNP Biogenesis and Metabolism, Department of Molecular Biology and Genetics, C.F. Møllers Alle 3, Building 1130, DK-8000 Aarhus, Denmark. <sup>9</sup>Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, USA. <sup>10</sup>The Finsen Laboratory, Rigshospitalet and Danish Stem Cell Centre (DanStem), University of Copenhagen, Ole Maaloes Vej 5, DK-2200, Denmark. <sup>11</sup>Roslin Institute, Edinburgh University, Easter Bush, Midlothian, Edinburgh EH25 9RG, UK. <sup>12</sup>Genomics Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road MS 64-121, Berkeley, California 94720, USA. <sup>13</sup>EMBL Outstation - Hinxton, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK. <sup>14</sup>RIKEN Preventive Medicine and Diagnosis Innovation Program, RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa 230-0045, Japan. <sup>15</sup>Department of Biosciences and Nutrition, Karolinska Institutet, Hälsovägen 7, SE-4183 Huddinge, Stockholm, Sweden. <sup>16</sup>Department of Clinical Genetics, VU University Medical Center, van der Boechorststraat 7, 1081 BT Amsterdam, Netherlands.

\*These authors contributed equally to this work.

†A list of authors and affiliations appears in the Supplementary Information.



**Figure 1 | Bidirectional capped RNAs is a signature feature of active enhancers.** **a**, Enhancers identified by co-occurrence of H3K27ac and H3K4me1 ChIP-seq data<sup>7</sup>, centred on P300 binding sites, in HeLa cells were overlaid with HeLa CAGE data (unique positions of CAGE tag 5' ends, smoothed by a 5-bp window), revealing a bidirectional transcription pattern. Horizontal axis shows the  $\pm 500$  bp region around enhancer midpoints. **b**, Density plot illustrating the difference in directionality of transcription

were observed in other cell lines (Supplementary Fig. 2a). Enhancer-associated reverse and forward strand transcription initiation events were, on average, separated by 180 base pairs (bp) and corresponded to nucleosome boundaries (Supplementary Figs 3 and 4). As a class, active HeLa-S3 enhancers had 231-fold more CAGE tags than polycomb-repressed enhancers, indicating that transcription is a marker for active usage. Indeed, ENCODE-predicted enhancers<sup>7</sup> with significant reporter activity<sup>8</sup> had greater CAGE expression levels than those lacking reporter activity ( $P < 4 \times 10^{-22}$ , Mann-Whitney *U* test). A lenient threshold on enhancer expression increased the validation rate of ENCODE enhancers from 27% to 57% (Supplementary Fig. 5).

Although capped RNAs of protein-coding gene promoters were strongly biased towards the sense direction, similar levels of capped RNA in both directions were detected at enhancers (Fig. 1b and Supplementary Fig. 2b, c). Thus, bidirectional capped RNAs is a signature feature of active enhancers. On this basis, we identified 43,011 enhancer candidates across 808 human CAGE libraries (see Supplementary Text and Supplementary Figs 6–8). Interestingly, the candidates were depleted of CpG islands (CGI) and repeats (with the exception of neural stem cells, see ref. 9).


To confirm the activity of newly identified candidate enhancers, we randomly selected 46 strong, 41 moderate and 36 low activity enhancers

according to FANTOM5-pooled CAGE tags mapped within  $\pm 300$  bp of 22,486 TSSs of RefSeq protein-coding genes and centre positions of 10,138 HeLa enhancers defined as above. **c**, Success rates of 184 *in vitro* enhancer assays in HeLa cells. Vertical axis shows the fraction of active enhancers (success defined by Student's *t*-test,  $P < 0.05$  versus random regions; also see Supplementary Fig. 9). Numbers of successful assays are shown on the respective bar. See main text for details.

(as defined by CAGE tag frequency in HeLa cells) and examined their activity using enhancer reporter assays compared to randomly selected untranscribed loci with regulatory potential in HeLa-S3 cells: 15 DHSs<sup>10</sup>, 26 ENCODE-predicted 'strong enhancers'<sup>7</sup> and 20 enhancers defined as in Fig. 1a (Supplementary Tables 2 and 3). Whereas 67.4–73.9% of the CAGE-defined enhancers showed significant reporter activity, only 20–33.3% of the untranscribed candidate regulatory regions were active (Fig. 1c and Supplementary Fig. 9a). The same trend was observed in HepG2 cells (Supplementary Fig. 10a, b). Corresponding promoter-less constructs showed that the enhancer transcription read-through is negligible (Supplementary Fig. 9b, c). Many CAGE-defined enhancers overlapped predicted ENCODE 'strong enhancers' or 'TSS' states (25% and 62%, respectively, for HeLa-S3), but there was no substantial difference in validation rates between these classes (Supplementary Fig. 10c, d). In summary, active CAGE-defined enhancers were much more likely to be validated in functional assays than untranscribed candidate enhancers defined by histone modifications or DHSs.

**Initiation and fate of enhancer RNAs versus mRNAs**

RNA-seq data from matching primary cells and tissues showed that  $\sim 95\%$  of RNAs originating from enhancers were unspliced and typically short (median 346 nucleotides)—a striking difference to mRNAs



**Figure 2 | Features distinguishing enhancer TSSs from mRNA TSSs.** **a**, Densities of the genomic and processed RNA lengths of transcripts starting from enhancer TSSs and mRNA TSSs using assembled RNA-seq reads from 13 pooled FANTOM5 libraries. **b**, Frequencies of RNA processing motifs (5' splice motif (5'SS, upper panel) and the transcription termination site hexamer (TTS, lower panel)) around enhancer and mRNA TSSs. Vertical axis shows the average number of predicted sites per kb within a certain window size from the TSS (horizontal axis) in which the motif search was done. Dashed lines indicate expected hit density from random genomic background. The window always starts at the gene or enhancer CAGE summits and expands in the sense direction. nCGI, non-CGI. **c**, Average nucleotide frequencies (top panel) and DNase I cleavage patterns (lower panel) of enhancer CAGE

peaks (arrow at +1 indicates position of the main enhancer CAGE peaks; direction of transcription goes left to right) reveal distinct cleavage patterns at sequences resembling the INR and TATA elements. **d**, *De novo* motif enrichment analyses around enhancers and non-enhancer FANTOM5 CAGE-defined TSSs (CAGE TSSs matching annotated TSSs are referred to as 'promoters'), contingent on CGI overlap. Top enriched/depleted motifs are shown along with their best-known motif match name. Enrichment versus random background is presented as a heat map. **e**, Vertical axis shows average HeLa CAGE expression fold change versus control at enhancers and RefSeq TSSs after exosome depletion. Horizontal axis shows position relative to the TSS or the centre of the enhancer. Translucent colours indicate the 95% confidence interval of the mean.

(19% unspliced, median 1,256 nucleotides) (Fig. 2a and Supplementary Fig. 11a–c). Unlike TSSs of mRNAs, which are enriched for predicted 5' splice sites but depleted of downstream polyadenylation signals<sup>11,12</sup>, enhancers showed no evidence of associated downstream RNA processing motifs, and thus resemble antisense promoter upstream transcripts (PROMPTs)<sup>11</sup> (Fig. 2b and Supplementary Fig. 11d). Most CAGE-defined enhancers gave rise to nuclear (>80%) and non-polyadenylated (~90%) RNAs<sup>13</sup> (Supplementary Fig. 11e). Based on RNA-seq, few enhancer RNAs overlap exons of known protein-coding genes or large intergenic noncoding RNAs (9 and 1 out of 4,208 enhancers detected, respectively), indicating that they are not a substantial source of alternative promoters for known genes (as in ref. 14).

TSS-associated, uncapped small RNAs (TSSa-RNAs), attributed to RNAPII protection and found immediately downstream of mRNA TSSs<sup>15,16</sup>, were detectable in the same positions downstream of enhancer TSSs (Supplementary Fig. 12), indicating that RNAPII initiation at enhancer and mRNA TSSs is similar. Indeed, CAGE-defined enhancer TSSs resembled the proximal position-specific sequence patterns of non-CGI RefSeq TSSs (Fig. 2c and Supplementary Fig. 13a). Furthermore, *de novo* motif analysis revealed sequence signatures in CAGE-defined enhancers closely resembling non-CGI promoters (Fig. 2d and Supplementary Fig. 13b).

Because of the similarity with PROMPTs, we reasoned that capped enhancer RNAs might be rapidly degraded by the exosome. Indeed, small interfering RNA-mediated depletion of the *SKIV2L2* (also known as MTR4) co-factor of the exosome complex resulted in a median 3.14-fold increase of capped enhancer-RNA abundance (Fig. 2e and Supplementary Fig. 14a, b), but only a negligible increase at mRNA TSSs. This increasing trend is similar to that of PROMPT regions upstream of TSSs, although the increase of enhancer RNAs was significantly higher ( $P < 4.6 \times 10^{-67}$ , Mann–Whitney *U* test; Fig. 2e and Supplementary Fig. 14b, c). Thus, the bidirectional transcriptional activity observed at enhancers is also present at promoters, as suggested previously<sup>17</sup>, but in promoters only the antisense RNA is degraded. Furthermore, the CAGE expression of enhancers in control and *SKIV2L2*-depleted cells was proportional (Supplementary Fig. 14d), indicating that virtually all identified enhancers produce exosome-sensitive RNAs. The number of detectable bidirectional CAGE peaks increased 1.7-fold upon *SKIV2L2* depletion and novel enhancer candidates had on average similar, but weaker, chromatin modification signals compared to control HeLa cells (Supplementary Fig. 14e).


### CAGE identifies cell-specific enhancer usage

To test whether CAGE expression can identify cell-type-specific enhancer usage *in vivo*, ChIP-seq (H3K27ac and H3K4me1), DNA methylation and triplicate CAGE analyses were performed in five primary blood cell types, and compared to published DHS data (<http://www.roadmapepigenomics.org/>, Supplementary Table 4). CAGE-defined enhancers were strongly supported by proximal H3K4me1/H3K27ac peaks (71%) and DHSs (87%) from the same cell type. Conversely, H3K4me1 and H3K27ac supported only 24% of DHSs distal to promoters and exons and only 4% of DHSs overlapped CAGE-defined enhancers (Supplementary Fig. 15), indicating that a minority of promoter-distal DHSs identify enhancers. From the opposite perspective, only 11% of H3K4me1/H3K27ac loci overlapped CAGE-defined enhancers and untranscribed loci showed weaker ChIP-seq signals than transcribed ones (Supplementary Fig. 16). Moreover, there was a clear correlation between CAGE, DNase I hypersensitivity, H3K4me1 and H3K27ac for CAGE-defined enhancers expressed in blood cells (Fig. 3a). Accordingly, cell-type-specific enhancer expression corresponds to cell-type-specific histone modifications (Fig. 3b). The majority of selected cell-type-specific enhancers could be validated in corresponding cell lines and were associated with cell-type-specific DNA demethylation (Supplementary Text, Supplementary Fig. 17 and Supplementary Tables 5–8, see also ref. 18). Thus, bidirectional CAGE pairs are robust predictors for cell-type-specific enhancer activity.

### An atlas of transcribed enhancers across human cells

The FANTOM5 CAGE library collection<sup>6</sup> enables the dissection of enhancer usage across cell types and tissues comprehensively sampled across the human body. Clustering based on enhancer expression clearly grouped functionally related samples together (Fig. 3c and Supplementary Figs 18 and 19). Although fetal and adult tissue often grouped together, two large fetal-specific clusters were identified: one brain-specific (pink) and one with diverse tissues (green). The fetal-brain cluster is associated with enhancers that are located close to known neural developmental genes, including *NEUROG2*, *SCRT2*, *POU3F2* and *MEF2C* (Supplementary Fig. 18b), for which gene expression patterns correlate with enhancer RNA abundance across libraries, suggesting regulatory interaction (see below). The results corroborate the functional relevance of these enhancers for tissue-specific gene expression and indicate that they are an important part of the regulatory programs of cellular differentiation and organogenesis.

To confirm that candidate enhancers can drive tissue-specific gene expression *in vivo*, five evolutionarily conserved CAGE-defined human enhancers (including the *POU3F2* and *MEF2C*-proximal enhancers



**Figure 3 | CAGE expression identifies cell-type-specific enhancer usage.**

**a**, Relationship between CAGE and histone modifications in blood cells. Rows represent CAGE-defined enhancers that are ordered based on hierarchical clustering of CAGE expression. Columns for the CAGE tags (pink) represent the expression intensity for three biological replicates. DNase I hypersensitivity and H3K27ac and H3K4me1 ChIP-seq signals  $\pm 1$  kb around the enhancer midpoints are shown in green, blue and orange, respectively. **b**, Mean signal of DNase-seq as well as ChIP-seq for H3K27ac and H3K4me1 (vertical axes) per cell type (rows) in  $\pm 1$  kb regions (horizontal axes) around enhancer midpoints, for enhancers with blood-cell type-specific CAGE expression (columns). **c**, Dendrogram resulting from agglomerative hierarchical clustering of tissue samples based on their enhancer expression: each leaf of the tree represents one CAGE tissue sample (for a labelled tree and the corresponding results on primary cell samples, see Supplementary Figs 18 and 19). Sub-trees dominated by one tissue/organ type or morphology are highlighted. Some of the enhancers responsible for the fetal-specific subgroup in the larger brain sub-tree are validated *in vivo* (Fig. 4).

identified above) were tested via Tol2-mediated transgenesis in zebrafish embryos. We observed tissue-specific enhancer activity with 3 of 5 fragments, which corresponded to the human enhancer tissue expression (Fig. 4). None of three control fragments without CAGE signal activated the *GATA2* promoter (Supplementary Table 9). Although the sample size is not high enough to reliably estimate the validation rates in zebrafish, the correlation between the enhancer usage profiles in zebrafish to those defined in human by CAGE is notable.

We grouped the primary cell and tissue samples into larger, mutually exclusive cell type and organ/tissue groups (referred to as facets), respectively, with similar function or morphology (Supplementary Tables 10 and 11). Figure 5 summarizes how many enhancers were detected in each facet and the degree of facet-specific CAGE expression (see also Supplementary Fig. 21). From the data we can draw several conclusions:

First, the majority of detected enhancers within any facet are not restricted to that facet. Exceptions, where facets use a higher fraction of specific enhancers, include immune cells, neurons, neural stem cells and hepatocytes amongst the cell-type facets, and brain, blood, liver and testis amongst the organ/tissue facets.

Second, despite their apparent promiscuity, enhancers are more generally detected in a much smaller subset of samples than mRNA transcripts (Supplementary Figs 21 and 22a, b), consistent with cell-line studies<sup>7</sup> and the higher specificity of ncRNAs in general<sup>13</sup>. Facets in which we detect many enhancers typically also have a higher fraction of facet-specific enhancers (Supplementary Fig. 22c, d).

Third, the number of detected expressed enhancers and mRNA transcripts is correlated (Supplementary Fig. 21b), but the number of detected expressed gene transcripts (>1 tag per million mapped reads (TPM)) is 19–34 fold larger than the number of detected enhancers

with the cut-offs used. Noteworthy exceptions include blood and immune cells, testis, thymus and spleen, which have high enhancer/gene ratios. Conversely, smooth and skeletal muscle and skin, bone and epithelia-related cells have low ratios. Differential exosome activity between cell types might affect these results, but there was no correlation between *SKIV2L2* mRNA expression and the number of enhancers detected (Supplementary Fig. 22e, f).

As expected, consensus motifs of known key regulators are over-represented in corresponding facet-specific enhancers, for instance ETS, C/EBP and NF- $\kappa$ B in monocyte-specific enhancers, RFX and SOX in neurons, and HNF1 and HNF4a in hepatocytes (Supplementary Fig. 23). Notably, the AP1 motif appears to be enriched across all facets, perhaps associated with a general role for AP1 in regulating open chromatin<sup>19</sup>.


### Expression clustering reveals ubiquitous enhancers

Hierarchical clustering of enhancers by facet expression revealed a small subset of enhancers (200 or 247, defined by primary cell or tissue facets, respectively) expressed in the large majority of facets (Supplementary Text, Supplementary Figs 24 and 25, and Supplementary Tables 12 and 13). Compared to other enhancers, these ubiquitous (u-) enhancers are 8 times more likely to overlap CGIs and they are twice as conserved (Supplementary Fig. 26a–c). U-enhancers overlap typical chromatin enhancer marks but have higher H3K4me3 signal (Supplementary Fig. 26d). Although they produce significantly longer ncRNAs than other enhancers (median 530 nucleotides,  $P < 1.5 \times 10^{-8}$ , Mann–Whitney *U* test), the transcripts remain predominantly (~78%) unspliced and significantly shorter ( $P < 4.2 \times 10^{-18}$ , Mann–Whitney *U* test) than mRNAs (Supplementary Figs 27 and 28), do not share exons with known genes, and are exosome-sensitive (Supplementary Fig. 14b). Therefore, it is unlikely that these are novel mRNA promoters. They are also highly enriched for P300 and cohesin ChIP-seq peaks<sup>20</sup> and RNAPII-mediated ChIA-PET signal<sup>21</sup> compared to other enhancers (Supplementary Fig. 26d). These results indicate that u-enhancers comprise a small but distinct subset of enhancers, which probably has specific regulatory functions used by virtually every human cell.


### Linking enhancer usage with TSS expression

A major challenge is to link enhancers to their target genes<sup>21,22</sup>. Uniquely, FANTOM5 CAGE allows for direct comparison between transcriptional activity of the enhancer and of putative target gene TSSs across a diverse set of human cells. Based on pairwise expression correlation, nearly half (40%) of the inferred TSS-associated enhancers (Methods) were linked with the nearest TSS, and 64% of enhancers have at least one correlated TSS within 500 kilobases. Several associations (10,260; 15.3%) are supported by ChIA-PET (RNAPII-mediated) interaction data<sup>21</sup>, and the supported fraction increases with the correlation threshold (Supplementary Fig. 29a). The fraction of supported associations is 4.8-fold higher than that of associations predicted from DNase I hypersensitivity correlations<sup>10</sup> (20.6% versus 4.3%, at the same correlation threshold), indicating that transcription is a better predictor of regulatory targets than chromatin accessibility. Conserved sequence motifs and ChIP-seq peaks also co-occurred significantly in associated enhancer-promoter pairs (Benjamini–Hochberg false discovery rate (FDR) < 0.05, binomial test), suggesting an additive or synergistic cooperation between enhancers and promoters at RNAPII foci.

On average, a RefSeq TSS was associated with 4.9 enhancers and an enhancer with 2.4 TSSs and we observed different regulatory architectures around genes (Supplementary Fig. 30). For example, at the beta-globin locus the CAGE expression patterns of four locus control region hypersensitive sites are highly correlated (Pearson's *r* between 0.88 and 0.98) with the expression of known target genes<sup>23,24</sup> *HBG2* and *HBD*, and to some extent *HBG1*.




**Figure 4 | *In vivo* validation in zebrafish of tissue-specific enhancers.** Validations of *in vivo* activity of CAGE-defined human enhancers CRE1, CRE2 and CRE3 in zebrafish embryos at long-pec stage. Each panel shows, from left to right, representative yellow fluorescent protein (YFP) and bright field images of embryos injected with the human enhancer *gata2* promoter reporter gene construct (left), YFP zoom-ins (middle) and CAGE expression in TPM in human tissues/cell types for the enhancer (right). Muscle (mu) and yolk syncytial layer (ysl) activities are background expression coming from the *gata2* promoter-containing reporter construct. All images are lateral, head to the left. Note the correspondence between zebrafish and human enhancer usage/ expression. Supplementary Fig. 20 shows UCSC browser images of each selected enhancer. **a**, CRE1, ~230 kb upstream of the *MEFC2* gene, drives highly robust expression in the brain (brain) and neural tube (nt). Right panel gives zoom-in overlay image showing expression in the forebrain (fb), midbrain (mid), hindbrain (hin) and spinal cord (sp). **b**, CRE2, 5 kb upstream of the *POU3F2* gene, is active in the floor plate (fp). **c**, CRE3, 10 kb upstream of the *SOX7* gene TSS, shows specific expression in the vasculature (including intersegmental vessels (iv), dorsal vein (dv) and dorsal aorta (da)).



**Figure 5 | Enhancer usage and specificity in groups of cells.** The upper panel gives the number of detected enhancers per million CAGE tags within each group (facet) of related cell type libraries. The expression specificity of the enhancers is shown as a heat map in the panel below. Colours show the fraction of expressed enhancers in each facet (columns) that are in each specificity range (rows). For corresponding plots on organ/tissue facets and genes, see Supplementary Fig. 21.

These observations call for computational models of enhancer regulation, in which multiple enhancers may work in concert to enhance the expression of a gene. To this end, we focused on 2,206 RefSeq TSSs for which the joint expression of nearby enhancers (the closest ten enhancers within 500 kb) is highly predictive of the gene expression.

Model shrinkage showed that in most cases, only one to three enhancers are necessary to explain the expression variance observed in the linked gene, and generally proximal enhancers are more predictive than distal ones (Fig. 6a, Supplementary Fig. 29b–d and Supplementary Text). One hypothesis explaining the function of multiple enhancers driving the



**Figure 6 | Linking enhancers to TSSs and disease-associated SNPs.** **a**, The proportional contribution (see Methods) of the 10 most proximal enhancers within 500 kb of a TSS in a model explaining gene expression variance (vertical axis) as a function of enhancer expression. *x* axis indicates the position of the enhancer relative to the TSS: 1 the closest, etc. Bars indicate interquartile ranges and dots medians. **b**, Relationship between the number of highly correlated (‘redundant’) enhancers per locus (horizontal axis) and the maximal expression (TPM) of the associated TSS in the same model over all CAGE libraries (vertical axis). Error bars as in **a**. **c**, GWAS SNP sets preferentially overrepresented

within enhancers, exons and mRNA promoters. Observed and expected overlaps are shown above bars. The vertical axis gives enrichment odds ratios. The horizontal axis shows GWAS traits or diseases. **d**, Diseases with GWAS-associated SNPs over-represented in enhancers of certain expression facets. The horizontal axis gives the odds ratio as in panel **c**, broken up by expression facets: each point represents the odds ratio of GWAS SNP enrichment for a disease (vertical axis) in a specific expression facet. Summary annotations of point clouds are shown. See also Supplementary Fig. 31.

same expression pattern is that they might confer higher transcriptional output of a gene<sup>25,26</sup>. Indeed, the number of highly correlated (redundant) enhancers close to TSSs (Supplementary Methods) increased with the observed maximal TSS expression over all libraries (Fig. 6b), implying that these enhancers are redundant in terms of transcription patterns but additive in terms of expression strength. Expression redundancy is also common in genomic clusters of closely spaced enhancers (24% of 815 identified genomic clusters, Supplementary Table 15). These are associated with TSSs of genes involved in immune and defence responses and, as suggested by a previous study<sup>27</sup>, have a higher expression than other enhancer-associated genes (eightfold increase on average).

### Disease-associated SNPs are enriched in enhancers

Many disease-associated SNPs are located outside of protein-coding exons and a large proportion of human genes display expression polymorphism<sup>28</sup>. Using the NHGRI genome-wide association studies (GWAS) catalogue<sup>29</sup> and extending the compilation of lead SNPs with proxy SNPs in strong linkage disequilibrium (similar to refs 30, 31), we identified diseases/traits whose associated SNPs overlapped enhancers, promoters, exons and random regions significantly more than expected by chance (Fisher's exact test  $P < 0.01$ , Supplementary Table 16). Disease-associated SNPs were over-represented in regulatory regions to a greater extent than in exons (Fig. 6c). For many traits where enriched disease-associated SNPs were within enhancers, enhancer activity was detected in pathologically relevant cell types (Fig. 6d and Supplementary Figs 31 and 32). Examples include Graves' disease-associated SNPs enriched in enhancers that are expressed predominantly in thyroid tissue, and similarly lymphocytes for chronic lymphocytic leukaemia. As a proof of concept, we validated the impact of two disease-associated regulatory SNPs within enhancers (Supplementary Fig. 33).

### Conclusions

The data presented here demonstrate that bidirectional capped RNAs, as measured by CAGE, are robust predictors of enhancer activity in a cell. Transcription is only measured at a fraction of chromatin-defined enhancers and few untranscribed enhancers show potential enhancer activity. This implies that many chromatin-defined enhancers are not regulatory active in that particular cellular state, but may be active in other cells of the same lineage<sup>32</sup> or are pre-marked for fast regulatory activity upon stimulation<sup>33</sup>. Of course, given the relative instability of enhancer RNAs some chromatin-defined sites may be active but fall below the limits of detection of CAGE.

Our results show that position-specific sequence signals upstream of the transcription initiation sites and the production of small, uncapped RNAs immediately downstream is present at both enhancers and mRNA promoters, suggesting similar mechanisms of initiation. Previous studies (for example refs 10, 34, 35) suggested that promoters and enhancers differ in motif composition. This view is not supported by the larger FANTOM5 data set. Instead, the differences reflect the local G+C content because transcribed enhancers tend to harbour low G+C content motifs like non-CGI promoters. Features distinguishing enhancers from mRNA promoters are (1) enhancer RNAs are exosome-sensitive regardless of direction whereas (sense) mRNAs have a longer half-life than their antisense counterpart; (2) enhancer RNAs are short, unspliced, nuclear and non-polyadenylated and (3) enhancers have downstream polyadenylation and 5' splice motif frequencies at genomic background level similar to antisense PROMPTs, whereas mRNAs are depleted of termination signals and enriched for 5' splice sites<sup>11,12</sup>.

The collection of active enhancers presented here provides a resource that complements the activity of the ENCODE consortium<sup>7</sup> across a much greater diversity of tissues and cellular states. It has clear applications in human genetics, to narrow the search windows for functional association, and for the definition of regulatory networks that underpin the processes of cellular differentiation and organogenesis in human development.

### METHODS SUMMARY

Single-molecule HeliScopeCAGE data was generated as described elsewhere<sup>6</sup>. Sequencing and processing of ribosomal RNA-depleted RNAs, short RNAs and H3K27ac or H3K4me1 ChIPs as well as the processing of publicly available DNase-seq data are described in the Methods.

Putative enhancers were identified from bidirectionally transcribed loci having divergent CAGE tag clusters separated by at most 400 bp (described in Supplementary Fig. 6a). We required loci to be divergently transcribed in at least one FANTOM5 sample, defined by CAGE tag 5' ends within 200 bp divergent strand-specific windows immediately flanking the loci midpoints. The expression of each enhancer in each FANTOM5 sample was quantified as the normalized sum of strand-specific sums of CAGE tags in these windows. A sample-set wide directionality score,  $D$ , for each locus over aggregated normalized reverse,  $R$ , and forward,  $F$ , strand window-expression values across all samples,  $D = (F - R) / (F + R)$ , were then used to filter putative enhancers to have low, non-promoter-like, directionality scores ( $|D| < 0.8$ ). Further filtering ensured enhancers to be located distant to TSSs and exons of protein- and noncoding genes.

Motif enrichment analyses were done using HOMER<sup>36</sup>. Regulatory targets of enhancers were predicted by correlation tests using the sample-set wide expression profiles of all enhancer-promoter pairs within 500 kb. The regulatory effects of multiple enhancers were modelled using linear regression followed by lasso-based model-shrinkage<sup>37</sup>.

Enhancer activity was tested *in vivo* in zebrafish embryos using Tol2-mediated transgenesis<sup>38</sup>. Expression patterns were documented at 48 h post fertilization using >200 eggs per construct. Large-scale *in vitro* validations on randomly selected enhancers were performed using firefly/*Renilla* luciferase reporter plasmids with enhancer sequences cloned upstream of an EF1 $\alpha$  basal promoter separated by a synthetic polyA signal/transcriptional pause site in a modified pGL4.10 (Promega) vector (Supplementary Fig. 9d). Full details are provided in the Methods.

**Online Content** Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.

Received 4 January; accepted 16 October 2013.

- Bulger, M. & Groudine, M. Enhancers: the abundance and function of regulatory sequences beyond promoters. *Dev. Biol.* **339**, 250–257 (2010).
- Lenhard, B., Sandelin, A. & Carninci, P. Metazoan promoters: emerging characteristics and insights into transcriptional regulation. *Nature Rev. Genet.* **13**, 233–245 (2012).
- Banerji, J., Rusconi, S. & Schaffner, W. Expression of a  $\beta$ -globin gene is enhanced by remote SV40 DNA sequences. *Cell* **27**, 299–308 (1981).
- Kim, T.-K. *et al.* Widespread transcription at neuronal activity-regulated enhancers. *Nature* **465**, 182–187 (2010).
- Kodzius, R. *et al.* CAGE: cap analysis of gene expression. *Nature Methods* **3**, 211–222 (2006).
- The FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian expression atlas. *Nature* <http://dx.doi.org/10.1038/nature13182> (this issue).
- The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57–74 (2012).
- Kheradpour, P. *et al.* Systematic dissection of regulatory motifs in 2000 predicted human enhancers using a massively parallel reporter assay. *Genome Res.* **23**, 800–811 (2013).
- Fort, A. *et al.* Deep transcriptome profiling of mammalian stem cells supports a regulatory role for retrotransposons in pluripotency maintenance. *Nature Genet.* (in the press).
- Thurman, R. E. *et al.* The accessible chromatin landscape of the human genome. *Nature* **489**, 75–82 (2012).
- Ntini, E. *et al.* Polyadenylation site-induced decay of upstream transcripts enforces promoter directionality. *Nature Struct. Mol. Biol.* **20**, 923–928 (2013).
- Almada, A. E., Wu, X., Kriz, A. J., Burge, C. B. & Sharp, P. A. Promoter directionality is controlled by U1 snRNP and polyadenylation signals. *Nature* **499**, 360–363 (2013).
- Djebali, S. *et al.* Landscape of transcription in human cells. *Nature* **489**, 101–108 (2012).
- Kowalczyk, M. S. *et al.* Intragenic enhancers act as alternative promoters. *Mol. Cell* **45**, 447–458 (2012).
- Valen, E. *et al.* Biogenic mechanisms and utilization of small RNAs derived from human protein-coding genes. *Nature Struct. Mol. Biol.* **18**, 1075–1082 (2011).
- Taft, R. J. *et al.* Tiny RNAs associated with transcription start sites in animals. *Nature Genet.* **41**, 572–578 (2009).
- Core, L. J., Waterfall, J. J. & Lis, J. T. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. *Science* **322**, 1845–1848 (2008).
- Rönnblad, M. *et al.* Analysis of the DNA methylome and transcriptome in granulopoiesis reveal timed changes and dynamic enhancer methylation. *Blood* <http://dx.doi.org/10.1182/blood-2013-02-482893> (in the press).

19. Biddie, S. C. *et al.* Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. *Mol. Cell* **43**, 145–155 (2011).
20. Schmidt, D. *et al.* A CTCF-independent role for cohesin in tissue-specific transcription. *Genome Res.* **20**, 578–588 (2010).
21. Li, G. *et al.* Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. *Cell* **148**, 84–98 (2012).
22. Chepelev, I., Wei, G., Wangsa, D., Tang, Q. & Zhao, K. Characterization of genome-wide enhancer-promoter interactions reveals co-expression of interacting genes and modes of higher order chromatin organization. *Cell Res.* **22**, 490–503 (2012).
23. Fraser, P., Pruzina, S., Antoniou, M. & Grosveld, F. Each hypersensitive site of the human beta-globin locus control region confers a different developmental pattern of expression on the globin genes. *Genes Dev.* **7**, 106–113 (1993).
24. Dostie, J. *et al.* Chromosome Conformation Capture Carbon Copy (5C): A massively parallel solution for mapping interactions between genomic elements. *Genome Res.* **16**, 1299–1309 (2006).
25. Barolo, S. Shadow enhancers: frequently asked questions about distributed cis-regulatory information and enhancer redundancy. *Bioessays* **34**, 135–141 (2012).
26. Schaffner, G., Schirm, S., Müller-Baden, B., Weber, F. & Schaffner, W. Redundancy of information in enhancers as a principle of mammalian transcription control. *J. Mol. Biol.* **201**, 81–90 (1988).
27. Whyte, W. A. *et al.* Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell* **153**, 307–319 (2013).
28. Göring, H. H. H. *et al.* Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. *Nature Genet.* **39**, 1208–1216 (2007).
29. Hindorf, L. A. *et al.* Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc. Natl Acad. Sci. USA* **106**, 9362–9367 (2009).
30. Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res.* **40**, D930–D934 (2012).
31. Maurano, M. T., Wang, H., Kuttyavin, T. & Stamatoyannopoulos, J. A. Widespread site-dependent buffering of human regulatory polymorphism. *PLoS Genet.* **8**, e1002599 (2012).
32. Mercer, E. M. *et al.* Multilineage priming of enhancer repertoires precedes commitment to the B and myeloid cell lineages in hematopoietic progenitors. *Immunity* **35**, 413–425 (2011).
33. Ostuni, R. *et al.* Latent enhancers activated by stimulation in differentiated cells. *Cell* **152**, 157–171 (2013).
34. Rada-Iglesias, A. *et al.* A unique chromatin signature uncovers early developmental enhancers in humans. *Nature* **470**, 279–283 (2011).
35. Shen, Y. *et al.* A map of the cis-regulatory sequences in the mouse genome. *Nature* **488**, 116–120 (2012).
36. Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–589 (2010).
37. Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. *J. Stat. Softw.* **33**, 1–22 (2010).
38. Gehrig, J. *et al.* Automated high-throughput mapping of promoter-enhancer interactions in zebrafish embryos. *Nature Methods* **6**, 911–916 (2009).

**Supplementary Information** is available in the online version of the paper.

**Acknowledgements** FANTOM5 was made possible by a Research Grant for RIKEN Omics Science Center from MEXT to Y.H. and a Grant of the Innovative Cell Biology by Innovative Technology (Cell Innovation Program) from the MEXT, Japan, to Y.H. The A.S. group was supported by funds from the European Research Council FP7/2007-2013/ERC no. 204135, the Novo Nordisk and Lundbeck foundations. Work in the M.R. group was funded by grants from the Deutsche Forschungsgemeinschaft (RE 1310/7, 11, 13) and Rudolf Bartling Stiftung. F.M. and I.M.E. were supported by “BOLD” Marie Curie ITN and “ZF-Health” Integrated project of the European Commission. We thank S. Noma, M. Sakai and H. Tarui for RNA-seq and sRNA-seq preparation, RIKEN GeNAS for generation and sequencing of the Heliscope CAGE libraries, Illumina RNA-seq and sRNA-seq, the Copenhagen National High-throughput DNA Sequencing Center for Illumina CAGE-seq, M. Edinger, P. Hoffmann and R. Eder for cell sorting, A. Albrechtsen, I. Moltke, W. Wasserman for advice, and the Netherlands Brain Bank for post-mortem human brain material.

**Author Contributions** R.A., I.H., E.A., E.V., K.L., Y.C., B.L., X.Z., M.J., H.K., T.F.M., T.L., N.B., O.R., A.M.B., J.K.B., C.J.M., N.R., F.O.B., M.R., A.S. made the computational analysis. J.B., M.B., T.L., H.K., N.K., J.K., H.S., M.I., C.O.D., A.R.R.F., P.C., Y.H. prepared and pre-processed CAGE and/or RNA-seq libraries. E.N., P.R.A., T.H.J., J.B., M.B. made the knockdown experiments followed by CAGE. C.G., C.S., L.S., J.R., D.G., M.R. made the blood cell ChIP experiments, methylation assays and *in vitro* blood cell validations. T.S., C.G., Y.I., Y.S., E.F., S.M., Y.N., A.R.R.F., P.C. and H.S. made the HeLa/HepG2 *in vitro* validations. I.M.E., R.A., A.S., F.M. designed and carried out zebrafish *in vivo* tests. R.A., C.G., I.H., C.S., E.A., E.V., F.M., I.M.E., P.C., A.R.R.F., M.B., J.B., A.L., C.D., D.A.H., P.H., M.R., A.S. interpreted results. R.A., C.G., I.H., E.V., I.M.E., J.B., F.M., D.A.H., M.R., A.S. wrote the paper with input from all authors. M.R. and A.S. coordinated and supervised the project.

**Author Information** The FANTOM5 atlas is accessible from <http://fantom.gsc.riken.jp/5>. FANTOM5 CAGE, RNA-seq and sRNA data have been deposited in DDBJ/EMBL/GenBank (accession codes DRA000991, DRA001101). Genome browser tracks for enhancers with user-definable expression specificity-constraints can be generated at <http://enhancer.binf.ku.dk>. Here, processed enhancer expression data, predefined enhancer tracks and motif finding results are also deposited. Blood-cell ChIP-seq data and CAGE data on exosome-depleted HeLa cells have been deposited in the NCBI GEO database (accession codes GSE40668, GSE49834). Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to A.R.R.F. (alistair.forrest@gmail.com), P.C. (carninci@riken.jp), M.R. (michael.rehli@ukr.de) or A.S. (albin@binf.ku.dk).

## METHODS

**CAGE data.** Single molecule HeliScopeCAGE<sup>39</sup> data was generated as described elsewhere<sup>6</sup>. We used a set of 432 primary cell, 135 tissue and 241 cell line samples that passed quality control measures of >500,000 Q20 Dolve (T.L. *et al.*, manuscript in preparation) mapped CAGE tags, RNA integrity and reproducibility (for further details, see ref. 6).

**Proof of concept analysis.** We defined silent and active enhancers from ENCODE HeLa-S3, GM12878 and K562 broad peaks, downloaded from the UCSC ENCODE repository, according to the co-existence of histone modifications H3K4me1, H3K27ac and H3K27me3. Active enhancers were defined as co-localized H3K4me1 and H3K27ac peaks with no H3K27me3 peak, whereas silent enhancers were considered loci with H3K4me1 and H3K27me3 peaks but no H3K27ac peak. Loci were filtered to be located distant to TSSs (500 bp) and exons (200 bp) of protein-coding genes, multi-exonic noncoding genes and mRNAs (from ENSEMBL, GENCODE (v10), RefSeq and UCSC, downloaded January 12, 2012), and other lncRNAs from a gene-centric set derived from literature<sup>40</sup> as well as manually annotated sense-antisense pairs (coding-noncoding and noncoding-noncoding sense-antisense pairs) with 5' expressed sequence tag (EST) and complementary DNA support, and 5' ESTs with no locus with protein-coding capacity. Transcriptional differences between active and silent enhancer sets were determined by comparing the average number of FANTOM5 CAGE tag 5' ends from the same ENCODE cell lines (pooled triplicates) in a window  $\pm 300$  bp around the H3K4me1 peak mid points.

The active enhancer sets of HeLa-S3, GM12878 and K562 cells were then centred on proximal (within 200 bp) P300 ENCODE binding site peaks (joint P300 and GATA1 peaks for K562) to derive centre positions. FANTOM5 CAGE data from the same ENCODE cell lines (pooled triplicates) were then overlaid over these centred enhancer regions and the absence (0) and presence (1) of (one or more) CAGE tag 5' ends in 10 bp non-overlapping windows were determined and an average profile was calculated to assess the average bidirectional pattern of transcription at chromatin-derived enhancers.

Pooled CAGE data from all FANTOM5 libraries (described above) were further overlaid with these regions and a directionality score based on the aggregate of CAGE tags falling within  $\pm 300$  bp from the centre positions were calculated to determine potential strand bias. For comparison, we repeated the same calculations for genomic regions  $\pm 300$  bp around TSSs of RefSeq protein coding genes. Directionality was calculated as  $(F - R) / (F + R)$ , where F and R is the sum of CAGE tags aligned on the forward and reverse strand, respectively. Directionality close to -1 or 1 indicates a unidirectional behaviour while 0 indicates perfectly balanced bidirectional transcription.

Positional cross correlations were calculated between reverse and forward CAGE tag 5' ends at ChIP-seq-derived active HeLa-S3 and GM12878 enhancer centre positions (as determined by P300 peaks)  $\pm 300$  bp (maximum lag 300) to identify their most likely separation. Cross correlations were also calculated in 300 bp windows (maximum lag 150) flanking the enhancer centres between CAGE 5' ends and ENCODE H2A.Z signals (from the same cell line) for HeLa-S3 and GM12878 as well as between CAGE 5' ends and 5' ends of ENCODE GM12878 micrococcal nuclease-digested nucleosome sequencing (MNase-seq) reads (9 pooled replicates). In the latter analysis, correlations were made using reads on the same strand. Pooled, unique CAGE tags (in which only one CAGE tag per bp was counted) were considered in all correlation analyses and enhancers were weighed according to the aggregated signal before subsequent averaging over lags not to make any library or enhancer have an undue influence.

### Reporter activity of ENCODE enhancers in relation to transcriptional status.

We used published<sup>8</sup> results on a massively parallel reporter assay measuring the activity of ENCODE-predicted enhancers in HepG2 and K562 cells. All results on non-scrambled sequences were considered, regardless of the level of conservation. 198 out of 738 tested K562 enhancers and 307 out of 1,136 tested HepG2 enhancers had significant enhancer reporter activity (as determined by the original publication). We determined the expression in 401 bp windows centred on mid points of ENCODE-predicted enhancers using FANTOM5 CAGE from the same cell lines. We further calculated the false discovery rate after a minimum expression threshold in the interval [0,0.5] TPM, as the fraction of non-significant enhancers among those fulfilling the expression cutoff.

**Identification of bidirectionally transcribed loci.** Bidirectionally transcribed loci were defined from a set of 1,714,047 forward and 1,597,186 reverse strand CAGE tag clusters (TCs) supported by at least two CAGE tags in at least one sample (TCs defined in ref. 6). Only TCs not overlapping antisense TCs were used. We identified 1,261,036 divergent (reverse-forward) TC pairs separated by at most 400 bp and merged all such pairs containing the same TC, while at the same time avoiding overlapping forward and reverse strand transcribed regions (prioritization by expression ranking), which resulted in 200,171 bidirectional loci (procedure illustrated in Supplementary Fig. 6a). A centre position was

defined for each bidirectional locus as the mid position between the rightmost reverse strand TC and leftmost forward strand TC included in the merged bidirectional pair. Each bidirectional locus was further associated with two 200 bp regions immediately flanking the centre position, one (left) for reverse strand transcription and one (right) for forward strand transcription, in a divergent manner. The merged bidirectional pairs were further required to be bidirectionally transcribed (CAGE tags supporting both windows flanking the centre) in at least one individual sample, and to have a greater aggregate of reverse CAGE tags (over all FANTOM5 samples) than forward CAGE tags in the 200 bp region associated with reverse strand transcription, and vice versa. These filtering steps resulted in 78,555 bidirectionally transcribed loci.

### Expression quantification of bidirectionally transcribed loci and prediction of enhancers.

We quantified the expression of bidirectional loci for each strand and 200 bp flanking window in each of the 432 primary cell, 135 tissue and 241 cell line samples separately by counting the CAGE tags whose 5' ends were located within these windows. The expression values of both flanking windows were normalized by converting tag counts to tags per million mapped reads (TPM) and further normalization between samples was done using the relative log expression (RLE) normalization procedure in edgeR<sup>41</sup>. The number of CAGE tags aligned on ChrM was subtracted from the total number of aligned CAGE tags in each library before normalization. The normalized expression values from both windows were used to calculate a sample-set wide directionality score,  $D$ , for each enhancer over aggregated normalized reverse,  $R$ , and forward,  $F$ , strand expression values across all samples (Supplementary Fig. 6a);  $D = (F - R) / (F + R)$ .  $D$  ranges between -1 and 1 and specifies the bias in expression to reverse and forward strand, respectively ( $D = 0$  means 50% reverse and 50% forward strand expression, while  $|D|$  close to 1 indicates unidirectional transcription). A directionality score calculated from pooled data is a good estimate of sample directionality (Supplementary Fig. 6b). Each bidirectional locus was assigned one expression value for each sample by summing the normalized expression of the two flanking windows.

Bidirectional loci were further filtered to have low, non-promoter-like, directionality scores ( $|D| < 0.8$ ) and to be located distant to TSSs and exons of protein- and noncoding genes (see 'Proof of concept analysis' above for details). This resulted in a final set of 43,011 putative enhancers.

We further tested whether the expression level for each sample and candidate enhancer was significantly greater than the genomic background (see construction of random genomic background regions below). A  $P$  value was calculated for each enhancer expression value for each primary cell, tissue and cell line sample by counting the fraction of random genomic regions with greater expression level in the same sample. Enhancers with  $P$  values less than 0.001 and Benjamini-Hochberg adjusted FDR  $< 0.05$  was considered transcribed in that sample. This analysis yielded binary expression values, which were used for constructing enhancer sets associated with each sample. In total, 38,554 enhancers were transcribed at a significant expression level in at least one primary cell or tissue sample. Below, we refer to this set as the 'robust set' of enhancers and indicate whenever it was used. For all analyses, we use the whole ('permissive') set of 43,011 enhancers if not otherwise mentioned.

**Construction of random genomic background regions.** We randomly sampled 100,000 genomic regions of 401 bp that were distal to TSSs and exons of known genes (same as the filtering procedure described above for bidirectionally transcribed loci). These were further filtered to not overlap with our set of 43,011 predicted enhancers, which yielded 98,942 random genomic regions whose expression levels were quantified and normalized in the same manner as described for bidirectional loci (above).

**Correlation between ENCODE epigenomic data and CAGE-defined enhancers.** Using the UCSC ENCODE repository data (downloaded and pooled 26 March 2012), we assessed the signal of RNA Polymerase II (RNAPII), the pooled transcription factor super track (all TFs), CCCTC-binding factor (CTCF), E1A binding protein P300, DNase I hypersensitive sites (DHSs) and two histone marks: H3K4me1 and H3K27ac around enhancers, TSSs and random genomic sites.

**Large scale enhancer reporter validations.** We randomly selected 125 CAGE-defined enhancers with significantly higher expression than random genomic regions in at least two out of three HeLa-S3 replicates. These were grouped according to HeLa-S3 expression tertiles: low (36), mid-level (41) and strong (46). These could be split up further according to overlap (mid position) with combined ENCODE (release January 2011) segmentations of Segway<sup>42</sup> and ChromHMM<sup>43</sup> chromatin state prediction: 25, 27 and 14 strongly, mid-level and lowly expressed CAGE enhancer overlapped ENCODE state 'E' ('strong enhancer') whereas 21, 16 and 22 strongly, mid-level and lowly expressed CAGE enhancer overlapped ENCODE state 'TSS'.

We further randomly selected 26 and 15 untranscribed (negligible amount of overlapping FANTOM5 HeLa-S3 CAGE tags) 500 bp regions centred on mid



positions of HeLa-S3 E states and HeLa-S3 ENCODE DHSs. Two literature-derived<sup>44</sup> HeLa-S3 positive enhancers and 4 random regions (see 'Construction of random genomic background regions') were used for comparison. For comparison, we also randomly selected 20 manually defined untranscribed HeLa-S3 chromatin-defined active enhancers (see 'Proof of concept analysis').

PCR primers for the amplification of enhancer and control regions were designed using the PerlPrimer tool<sup>45</sup>, and purchased from Operon Ltd Primers included BamHI or Sall restriction sites for cloning and sequences are listed in Supplementary Tables 2 and 3. Control fragments ranged between 420 and 1,452 bp. Enhancer fragments usually included a 500 bp window around the mid-point of our predicted enhancers and depending on the availability of unique primer sequences, enhancer fragments ranged between 470 and 840 bp.

We inserted an EF1 $\alpha$  basal promoter fragment into HindIII and NheI sites of the multiple cloning site in the promoter-less pGL4.10 (Promega) to construct the pGL4.10EF1 $\alpha$  vector. We next removed the BamHI and Sall containing fragment located downstream of the SV40 late poly(A) signal, and re-inserted the fragment at the SpeI site that is located upstream of the synthetic poly(A) signal/transcriptional pause site to generate modified versions of pGL4.10EF1 $\alpha$  and pGL4.10 (see Supplementary Fig. 9d).

Enhancer and control regions were PCR-amplified using KOD plus polymerase (Toyobo) from HEK-293T gDNA, digested with BamHI and Sall (Takara Bio), and purified using the E-Gel SizeSelect system (Life Technologies). Five  $\mu$ l of purified PCR products were ligated with 100 ng of the BamHI- and Sall-digested modified pGL4.10EF1 $\alpha$  and pGL4.10 plasmids using Ligation-high (Toyobo), and transformed into DH5 $\alpha$  competent cells (Toyobo). Correct insertion of the PCR products into the plasmids was checked by colony PCR. Vectors were purified using the QIAGEN Plasmid Plus 96 Miniprep Kit (Qiagen).

HeLa-S3 cells (JCRB Cell Bank) were cultured in MEM (WAKO) supplemented with 10% FBS (Nichirei Bioscience Inc., lot no. 7G0031), 100 Units ml<sup>-1</sup> penicillin and 100  $\mu$ g ml<sup>-1</sup> streptomycin (both Life Technologies). HepG2 Cells (RIKEN BRC) were cultured in DMEM (Life Technologies) supplemented with 10% FBS (Nichirei Bioscience Inc., Lot No. 7G0031), and MEM (WAKO) supplemented with 10% FBS (Nichirei Bioscience Inc., lot no. 7G0031), 100 Units penicillin and 100  $\mu$ g ml<sup>-1</sup> streptomycin (Life Technologies). Cell lines were seeded into 96 well plates at a density of  $7.5 \times 10^3$  cells per well one day before transfection. Firefly luciferase reporter plasmids (190 ng) and 10 ng of pGL4.73 *Renilla* luciferase plasmid (Promega) were co-transfected into HepG2 or HeLa-S3 cells using Lipofectamine (Life Technologies) according to the manufacturer's instruction. Each transfection was independently performed three times. After 24 h, the luciferase activities were measured by GloMax 96 Microplate luminometer (Promega) using the Dual-glo luciferase assay system (Promega) according to the manufacturer's instruction.

**Sequence motif analysis on global CAGE enhancer and promoter sets.** To compare motif signatures characterizing bidirectionally transcribed enhancers (permissive set) with those of CAGE-defined promoters, we used the set of 184,827 robust human CAGE clusters defined by ref. 6 separated into 61,322 CGI and 123,505 nonCGI-associated clusters. We made further subsets of these CAGE clusters, contingent on their overlap with annotated TSSs from Refseq and Gencode. We merged overlapping extended CAGE clusters (-300, +50; based on the robust cluster set; average size nonCGI: 422 bp; average size CGI: 544 bp) contingent on CGI status and subtracted CAGE cluster regions that overlapped with extended enhancers (mid position  $\pm$  200 bp).

This created five sets of regions representing non-overlapping bidirectional enhancers, nonCGI promoters and CGI promoters (annotated and full sets for the two latter ones). Motif enrichment was analysed using HOMER<sup>36</sup> version 3, a suite of tools for motif discovery and next-generation sequencing analysis (<http://biowhat.ucsd.edu/homer/>). Sequences of the three region sets (enhancers, nonCGI and CGI promoters) were compared to equal numbers of randomly selected genomic fragments of the average region size, matched for GC content and auto-normalized to remove bias from lower-order oligo sequences. After masking repeats, motif enrichment was calculated using the cumulative binomial distribution by considering the total number of target and background sequence regions containing at least one instance of the motif. One hundred motifs were searched for a range of motif lengths (7–14 bp) resulting in a set of 800 *de novo* motifs per set. After filtering redundant motifs, the top 50 motifs resulting from each search were combined, remapped and ranked according to enrichment (depletion) in the enhancer set. In parallel, we also used HOMER to calculate the enrichment of ChIP-seq derived known transcription factor motifs. Motif collections including search parameters are deposited in a web database at <http://enhancer.binf.ku.dk>. Histograms of PhastCons scores were generated using the annotation tool in HOMER.

**Analysis of splice site and termination signals downstream of CAGE enhancer TSSs and promoter TSSs.** To identify motifs downstream of TSSs potentially

differing between the structurally related bidirectionally transcribed enhancer TSSs and nonCGI-associated promoter TSSs, we extracted 600 bp regions downstream of each TSS and performed comparative *de novo* motif searches using HOMER. Here, we analysed one set using the other set as background (corrected for region size, matched for GC content and auto-normalized) to calculate motif enrichment only on the given strand. The top motif enriched downstream of nCGI promoters was the 5'-splice site motif. Genomic distributions of the enriched splice site motif, as well as the AATAAA termination signal were generated using HOMER.

**RNA-seq samples and library preparation.** Prior to preparation of sequencing libraries, rRNA was removed by poly(A)<sup>+</sup> selection (CD19+ B-cells, CD8+ T-cells, 500 ng) or rRNA depletion (fetal heart, 1  $\mu$ g). Poly(A)<sup>+</sup> selection was done twice by using Dynabeads Oligo(dT)<sub>25</sub> (Life Technologies) according to the manufacturer's manual. rRNA depletion was done by using Ribo-Zero rRNA removal kit (Epicentre, Illumina) according to the manual. The treated RNA was dissolved in 20  $\mu$ l water.

The pretreated RNA was then fragmented by heating at 70 °C for 3.5 min in fragmentation buffer (Ambion), followed by immediate chilling on ice and addition of 1  $\mu$ l of Stop solution. Fragmented RNA was purified with the RNeasy MinElute kit (Qiagen) following the instructions of the manufacturer except 675  $\mu$ l of 100% ethanol is used in step two, instead of 500  $\mu$ l. Purified RNA was dephosphorylated in phosphatase buffer (New England Biolabs) with 5 U of Antarctic phosphatase (New England Biolabs) and 40 U of RNaseOut (Life Technologies) at 37 °C for 30 min followed by 5 min at 65 °C. After chilling on ice RNA was phosphorylated by addition of the following reagents; 5  $\mu$ l of 10  $\times$  PNK buffer, 20 U of T4 polynucleotide kinase (New England Biolabs), 5  $\mu$ l of 10 mM ATP (Epicentre, Illumina), 40 U of RNaseOut, 17  $\mu$ l of water. The reaction was incubated at 37 °C for 60 min. Phosphorylated RNA was purified with the RNeasy MinElute kit (Qiagen) as described above. Purified RNA was concentrated to 6  $\mu$ l by vacuum centrifugation on a SpeedVac (Eppendorf). One  $\mu$ l of 2  $\mu$ M pre-adenylated 3' DNA adaptor, 5'-App/ATCTCGTATGCCGTCTTCTGCTT-3' was added to the concentrated RNA. After incubation at 70 °C for 2 min followed by chilling on ice for 2 min, the following reagents were added to ligate the adaptor at the 3' end of the RNA; 1  $\mu$ l of 10  $\times$  T4 RNA ligase 2 truncated buffer, 0.8  $\mu$ l of 100 mM MgCl<sub>2</sub>, 20 U of RNaseOUT and 200 U of RNA ligase 2 truncated (New England Biolabs). After the incubation at 20 °C for 60 min, 1  $\mu$ l of heat-denatured 5'  $\mu$ M 5' RNA adaptor, 5'-GUUCAGAGUUCUACAGUCCGACGAUCGAAA-3' was ligated with 3' adaptor ligation products with 20 U of T4 RNA ligase 1 (New England Biolabs) and 1  $\mu$ l of 10 mM ATP (New England Biolabs) at 20 °C for 60 min. 4  $\mu$ l of adaptor ligated RNA was mixed with 1  $\mu$ l of 20  $\mu$ M RT Primer, 5'-CAAGCAGAAGACGGCATAACGA-3', followed by incubation at 70 °C for 2 min, and immediately kept on ice. The reverse transcription reaction was done with 2  $\mu$ l 5  $\times$  Prime Script buffer, 1  $\mu$ l of 10 mM dNTP, 20 U of RNaseOUT and 200 U of PrimeScript Reverse Transcriptase (TakaraBIO) at 44 °C for 30 min. The cDNA product was amplified by PCR with 10  $\mu$ l of 5  $\times$  HF buffer, 1.25  $\mu$ l of 10 mM each dNTP mix, 2  $\mu$ l of 10  $\mu$ M FWD primer, 5'-AATGATACGCGCACCACCGACAGGTTTCAGATTCTACAGTCCGA-3', 2  $\mu$ l of RT primer and 1 U of Phusion High-Fidelity DNA Polymerase (New England Biolabs). PCR was carried out in a total volume of 50  $\mu$ l with the following thermal program; 98 °C for 30 s, 12 PCR cycles of 10 s at 98 °C, 30 s at 60 °C, and 15 s at 72 °C, followed by 72 °C for 5 min and then kept at 4 °C. Remaining PCR primers were removed twice by using 1.2 volumes of AMPure XP beads (Beckman Coulter). The resulting libraries were checked for size and concentration by BioAnalyzer (Agilent) using the High-Sensitivity DNA Kit (Agilent). Qualified sequencing libraries were loaded on the HiSeq2000 (Illumina) using the custom sequencing primer, 5'-CGACAGGTTTCAGAGTTCTACAGTCCGACGATCGAAA-3'.

All RNA-seq samples profiled in this study were also profiled in the FANTOM5 promoterome manuscript and are described in detail there<sup>6</sup>. Briefly all human samples used in the project were either exempted material (available in public collections or commercially available), or provided under informed consent. All non-exempt material is covered under RIKEN Yokohama Ethics applications (H17-34 and H21-14). For the samples profiled by RNA-seq, the human fetal heart RNA was purchased from Clontech (Catalogue no.636583). CD19+ B-cells and CD8+ T-cells were isolated using the pluriBead system (huCD4/CD8 cascade and huCD19 single; PluriSelect). RNA was then extracted using the miRNeasy kit (Qiagen). **RNA-seq mapping and transcript assembly.** Single-end 100 bp long reads from libraries originating from the similar cell sources (all six "CD19+ B cells" libraries, all six "CD8+ T cells" libraries and one "Fetal heart" library) were processed together via the Moirai pipeline (Hasegawa, Y. *et al.*, manuscript in preparation). The processing steps implemented within the Moirai pipeline included (1) raw sequenced reads polyA tail and "CTGTAGGCCACCATCAAT" adaptor clipping using FASTQ/A Clipper from FASTX-Toolkit ([http://hannonlab.cshl.edu/fastx\\_toolkit/](http://hannonlab.cshl.edu/fastx_toolkit/)), (2) removal of sequenced reads containing "N" and sequences similar to

ribosomal RNA using rRNA<sub>ust</sub> version 1.02 (T.L. *et al.*, manuscript in preparation), and (3) mapping the resulting reads against the hg19 human genome using TopHat<sup>46</sup> (version 1.4.1) using both TopHat *de novo* junction finding mode and known exon-exon junctions extracted from GENCODE V10, with all the other parameters set to their default values. Mapped reads flagged as PCR duplicates were removed and the remaining TopHat aligned reads were then assembled using Cufflinks<sup>47</sup> (version 1.3.0) with Cufflinks parameters set to their default values.

**Assessment of lengths of RNAs emanating from enhancers and promoters.** All Cufflinks assembled transcripts, whose 5' ends, regardless of strand, were located within the outer boundaries of CAGE enhancers or, on the same strand, within 200 bp (upstream or downstream) of a GENCODE (v10) protein-coding TSS were considered for further analysis. For these Cufflinks transcripts we calculated their (intron-less) RNA length, (possibly intron-containing) genomic length as the genomic distance between their 5' and 3' ends, as well as their number of exons. Exons of Cufflinks transcripts with 5' ends in enhancers were further checked for at least 50% (reciprocal) overlap with exons of GENCODE (v10) known, level 1, protein-coding genes and lincRNAs. We repeated the same analysis specifically for u-enhancers.

**Small RNA library preparation and mapping.** Short RNA-seq sequencing libraries were prepared as 24-plex using the TruSeq Small RNA Sample Prep Kit (Illumina) following the manufacturer's manual. All starting sources were 1 µg of total RNA. The prepared sequencing libraries were loaded on a HiSeq2000 (Illumina). All samples profiled in this study were also profiled in the FANTOM5 promoterome paper<sup>9</sup> and are described in detail there. Briefly, all human samples used in the project were either exempted material (available in public collections or commercially available), or provided under informed consent. All non-exempt material is covered under RIKEN Yokohama Ethics applications (H17-34 and H21-14). For the samples profiled by sRNA-seq, the human fetal heart RNA was purchased from Clontech (catalogue no.636583). CD19+ B-cells and CD8+ T-cells were isolated using the pluriBead system (huCD4/CD8 cascade and huCD19 single; PluriSelect). RNA was then extracted using the miRNeasy kit (Qiagen).

Short RNAs were profiled using the Truseq protocol from Illumina, using an 8-plex. The 8-plex was first split by barcode and the resulting FASTQ sequences trimmed of the 3' adaptor sequence. Sequences with low quality base N were removed. Ribosomal RNA sequences were then removed using the rRNA<sub>ust</sub> program. Remaining reads were then mapped using BWA version is 0.5.9(r16) and multimappers were randomly assigned.

**Analysis of small RNAs at enhancer TSSs and promoter TSSs.** 5' and 3' ends of mapped sRNAs as well as pooled CAGE 5' ends were overlaid windows of 601 bp centred on forward strand summits of enhancer-defining CAGE tag clusters and sense strand summits in promoters of RefSeq protein-coding genes. The average cross-correlation between CAGE 5' ends and sRNA 3' ends were calculated in these windows allowing a max lag of 300. For footprint plots, reads mapping to the same genomic locations were only counted once not to make any library or genomic region have an undue influence.

**HeLa cells culturing and SKIV2L2 depletion.** HeLa cells were grown in DMEM medium supplemented with 10% fetal bovine serum at 37 °C and 5% CO<sub>2</sub>. siRNA-mediated knockdown of either EGFP(control), and SKIV2L2 (MTR4) were performed using 22 nM of siRNA and Lipofectamin2000 (Invitrogen) as transfecting agent. A second hit of 22 nM siRNA was given after 48 h. Cells were collected an additional 48 h after the second hit, and protein depletion was verified by western blotting analysis as described elsewhere<sup>48</sup>. The following siRNA sequences were used:

```
egfp GACGUAACGGCCACAAGU[dT][dT]
egfp_as ACUUGUGGCCGUUUACGUC[dT][dT]
SKIV2L2 CAAUUAAGGCUCUGAGUAA[dT][dT]
SKIV2L2_as UUACUCAGAGCCUUAUUG[dT][dT]
```

**HeLa CAGE library preparations and data processing.** CAGE libraries were prepared from 5 µg of total RNA purified from 2 × 10<sup>6</sup> HeLa cells using the Purelink mini kit (Ambion) with 1% 2-mercaptoethanol (Sigma) and on-column DNase I treatment (Ambion) as recommended by manufacturer. CAGE libraries were prepared as described previously<sup>9</sup>. Prior to sequencing four libraries with different barcodes were pooled and applied to the same sequencing lane. The libraries were sequenced on a HiSeq2000 instrument (Illumina). To compensate for the low complexity in 5' end of the CAGE libraries 30% Phi-X spike-in were added to each sequencing lane as recommended by Illumina. CAGE reads were assigned to their respective originating sample according to identically matching barcodes. Assigned reads were trimmed to remove linker sequences and subsequently filtered for a minimum sequencing quality of 30 in 50% of the bases using the FASTX-Toolkit ([http://hannonlab.cshl.edu/fastx\\_toolkit/](http://hannonlab.cshl.edu/fastx_toolkit/)). Mapping to the human genome (hg19) was performed using Bowtie<sup>50</sup> (version 0.12.7), allowing for multiple good alignments and subsequently filtering for uniquely mapping reads. Reads that mapped to unplaced chromosome patches or chrM were discarded.

#### Assessment of degradation rates of RNAs emanating from CAGE enhancers and promoters.

Bidirectionally transcribed loci were identified in the same way as with pooled FANTOM5 CAGE libraries (see 'Identification of bidirectionally transcribed loci' and 'Expression quantification of bidirectionally transcribed loci and prediction of enhancers' above) from tag clusters (as defined in<sup>51</sup>) derived from pooled HeLa CAGE (mock treated control, SKIV2L2) libraries. From 5,892 bidirectional loci distant to TSSs and exons, 4,196 were predicted to be enhancers based on balanced directionality of transcription of which 3,896 had significantly greater expression than random genomic regions in at least one library. These were then overlapped with the whole set of FANTOM5 CAGE enhancers to estimate the fraction of unseen transcribed enhancers.

The expression fold change of HeLa depleted of SKIV2L2 compared to mock-treated control were assessed and compared between expressed HeLa CAGE enhancers, promoters of RefSeq protein-coding genes in general and broken up into CpG and non-CpG promoters, and ubiquitous FANTOM5 CAGE enhancers.

We further calculated the average footprints of H3K4me1, H3K4me2 and H3K27ac from ENCODE (Broad, Bernstein) signal files in 601 bp windows centred on mid points of enhancers identified in HeLa cells and those that were novel in SKIV2L2<sup>-</sup>.

**Purification of blood cell types.** Peripheral blood mononuclear cells were isolated from leukapheresis products of healthy volunteers by density gradient centrifugation over Ficoll/Hypaque (Biochrom AG). Collection of blood cells from healthy donors was performed in compliance with the Helsinki Declaration. All donors signed an informed consent. The leukapheresis procedure and subsequent purification of peripheral blood cells was approved by the local ethical committee (reference number 92-1782 and 09/066c). CD4+ cells were enriched using magnetically labelled human CD4 MicroBeads (Miltenyi Biotec) and the Midi-MACS system (Miltenyi Biotec). The CD4+ fraction was stained with CD4 FITC (fluorescein isothiocyanate; Becton Dickinson, catalogue no. 345768), CD25 phycoerythrin (PE; Becton Dickinson, catalogue no. 341011) and CD45RA allophycocyanin (APC) and CD3+CD4+CD25- T cells were sorted on a FACS-Aria high-speed cell sorter (BD Biosciences). CD8+ cells were enriched using magnetically labelled human CD8 MicroBeads (Miltenyi). The CD8+ fraction was stained with CD3 FITC (Becton Dickinson, catalogue no. 345763) and CD8 APC (Becton Dickinson, catalogue no. 345775) and sorted for CD3+CD8+ T cells. CD19+ and CD56+ cells were enriched from the CD8- fraction using magnetically labelled human CD19 and CD56 MicroBeads (Miltenyi). Enriched cells were stained with CD3 FITC (Becton Dickinson, catalogue no. 345763), CD19 PE (Becton Dickinson, catalogue no. 345777) and CD56 APC (Becton Dickinson, catalogue no. 341027) and sorted into CD3+CD19+ B cells and CD3+CD56+ natural killer (NK) cells. Purification of blood monocytes is described elsewhere<sup>52</sup>.

**Generation of ChIP data for blood cells.** Chromatin was obtained from CD4+CD25- T cells, CD8+ T cells, CD19+ B cells, and CD56+ NK cells of two healthy male donors each. Chromatin immunoprecipitation (ChIP) for H3K4me1 and H3K27ac and library construction were done essentially as described elsewhere<sup>52</sup>. Sequence tags were mapped to the current human reference sequence (GRCh37/hg19) using Bowtie<sup>50</sup> and only uniquely mapped tags were used for downstream analyses. H3K4me1 and H3K27ac ChIP-seq data for CD14+ monocytes was generated elsewhere<sup>52</sup>. Complementary DNase hypersensitivity sequencing data was obtained from the Epigenetics Roadmap project (<http://www.roadmapepigenomics.org>) and mapped as above. Blood cell ChIP-seq data have been deposited with the NCBI GEO database (accession code GSE40668) and UCSC Genome Browser track hub data of the entire blood cell data set can be found at <http://www.ag-rehli.de/NGSdata.htm>. Also see Supplementary Table 4.

**Clustering of blood cell CAGE and epigenetics data.** CAGE samples corresponding to CD4+, CD8+, B cells, NK cells and monocytes were selected in triplicates from among the set of primary cell samples. Based on the total set of 43,011 permissive enhancers, a subset of 6,609 blood-expressed enhancers was defined as being significantly expressed above genomic background (described above) in at least two of the triplicate samples for at least one blood cell type. This subset of enhancers was clustered for heat map visualization using complete linkage agglomerative hierarchical clustering based on enhancer usage per cell type (binary matrix) and Manhattan distance.

Enhancers were defined as being specifically expressed in one blood cell type if having a pairwise log<sub>2</sub> fold change > 1.5 with respect to the other four blood cell types. The fold change was calculated based on the mean expression over triplicate samples per cell type. Footprints for DNase I hypersensitivity (DHS), H3K4me1 and H3K27ac were calculated per cell-type-specific enhancer set and cell type by extension of reads to 200 bp and overlap aggregation for a window of ± 1 kb around enhancer midpoint as the mean TPM signal over all enhancers in that specific subset.

Peak-calling was done using MACS2<sup>53</sup> on pooled data for DHS, H3K4me1 and H3K27ac. Per cell type, peaks were regarded as significant if the peak summit fell within the upper 1 percentile of the background signal (max values in 92,604 random 1 kb non-TSS non-enhancer regions). DHS regions were defined as  $\pm 500$  bp around peak summits. Since ChIP-Seq signals for H3K4me1 and H3K27ac often form bimodal peaks around enhancer sites, peak regions were defined as merged regions resulting from overlapping  $\pm 500$  bp regions around MACS2 called peak summits.

**Transient enhancer-reporter assays in blood cells.** Selected blood cell-type-specific enhancer regions (ranging from 800–1,200 bp) were PCR-amplified from human genomic DNA and cloned directly into the CpG-free pCpGL-CMV/EF1 vector<sup>54,55</sup> replacing the CMV enhancer with the DMR regions. Primer sequences are given in Supplementary Table 5. All inserts were verified by sequencing. For transient transfections, plasmids were isolated and purified using the EndoFree Plasmid Kit (Qiagen). Each luciferase construct was transiently transfected into three model cell lines (the monocytic THP-1 cell line, the Jurkat T cell line, and the B cell lymphoma cell line DAUDI). THP-1 and DAUDI cells were transfected using DEAE-dextran with 200 ng reporter plasmid and 10 ng *Renilla* control vector essentially as described<sup>56</sup>. Jurkat cells were transfected as described elsewhere<sup>54</sup>. The transfected cell lines were cultivated for 48 h, collected, and cell lysates were assayed for firefly and *Renilla* luciferase activity using the Dual Luciferase Reporter Assay System (Promega) on a Lumat LB9501 (Berthold). Firefly luciferase activity of individual transfections was normalized against *Renilla* luciferase activity. Transfections correspond to at least three independent experiments measured in duplicates.

To correct enhancer activity for the amount of read-through that is potentially generated from the enhancer TSS, we additionally generated constructs lacking the basal EF1 $\alpha$  promoter for all B cell-specific constructs. Relative luciferase activities generated by read-through activity were subtracted from the activity of enhancer/EF1 constructs to reveal 'true' enhancer activities of individual regions. To further determine the position and activity of reporter TSS, 5' rapid amplification of cDNA ends (RACE)-PCR for the luciferase gene was performed as follows: RNA of transfected DAUDI cells was reverse transcribed using the SMARTer RACE cDNA Amplification Kit (Clontech) according to the manufacturers' instructions. Rapid Amplification of luciferase 5' cDNA ends (5' RACE) was performed with the Advantage 2 Polymerase System (Clontech) and a LUC specific primer (5'-CATGGCTTCTGCCAGCCTCACAGACATC-3') using the recommended touchdown-PCR program. 15  $\mu$ l of the PCR products were analysed by agarose gel electrophoresis (2.5%). In addition, fragments were cloned using the StrataClone PCR cloning Kit (Agilent) according to the manufacturers' instructions and sequenced (Life Technologies).

**Mass spectrometry analysis of bisulphite-converted DNA.** For the set of genomic regions that were also used in transient enhancer-reporter assays, PCR primers were designed using the MethPrimer web tool<sup>57</sup> and purchased from Sigma-Aldrich (for sequences see Supplementary Table 7). Sodium bisulphite conversion was performed using the EZ DNA methylation kit (Zymo Research) using 200–1,000 ng of genomic DNA from CD4+CD25– T cells, CD8+ T cells, CD14+ monocytes, CD19+ B cells, and CD56+ NK cells (two donors each) and an alternative conversion protocol. Amplification of target regions was followed by SAP treatment, reverse transcription and subsequent RNA base-specific cleavage (MassCLEAVE) as previously described<sup>58</sup>. Cleavage products were loaded onto silicon chips (SpectroCHIP) and analysed by MALDI-TOF mass spectrometry (MassARRAY Compact MALDI-TOF, Sequenom). Methylation was quantified from mass spectra using the EpiTyper software (Sequenom), and averaging methylation levels of CpG dinucleotides located in the central DNase hypersensitive (nucleosome-free) region that is flanked by CAGE clusters. The methylation data for individual CpGs are provided in Supplementary Table 8.

**Definition of expression facets and differentially expressed 'specific' facets.** Cell and UBERON ontology term mappings were extracted from the FANTOM5 sample ontology<sup>6</sup> for primary cell and tissue samples, respectively, using indirect and direct 'is\_a' and 'part\_of' relationships. Ontology terms were manually selected to construct groups (facets) of samples that were mutually exclusive and to cover as broad histological and functional annotations as possible. 362 primary cell samples and 138 tissue and whole blood samples were grouped into 69 cell type facets and 41 organ/tissue facets, respectively (the groupings of samples into facets are provided in Supplementary Tables 10 and 11). A few samples were ignored because they were difficult to assign to a facet with certainty, which means that the number of samples within facets is slightly lower than the total number of samples.

For each facet, we defined a set of robustly expressed enhancers from the union of significantly expressed enhancers (see calculation of expression significance above) associated with each contained sample.

For motif search (see below), we identified the set of robust enhancers that were significantly deviating between facets using Kruskal–Wallis rank sum tests

(Benjamini–Hochberg FDR < 0.05) and performed pair-wise post-hoc tests (Nemenyi–Damico–Wolfe–Dunn (NDWD) test<sup>59,60</sup> using the R coin package<sup>61</sup> to identify enhancers with significant differential expression (Bonferroni single-step adjusted  $P < 0.05$ ) between facets. Cell type facets and tissue/organ facets were analysed separately. Each enhancer was considered differentially expressed in a facet with at least one pair-wise significant differential expression and overall positive standard linear statistics. This procedure means that we, for each robust enhancer, selected the facets, if any, with strong overall differential expression compared to all other facets. It should be noted that differential expression in this sense is not equivalent to facet-specific (exclusive) expression.

**Specificity and usage level analysis.** For each robust enhancer, we calculated a 'specificity' score across cell type and organ/tissue facets. The specificity score was defined to range between 0 and 1, where 0 means unspecific (ubiquitously expressed across facets) and 1 means specific (exclusively expressed in one facet).

In detail,  $\text{specificity}(X) = 1 - (\text{entropy}(X)/\log_2(N))$ , where  $X$  is a vector of sample-average expression values for an enhancer over all facets (cell types and organs/tissues were analysed separately) and  $N$  its cardinality ( $|X|$ , the number of facets). The same calculations were done for TPM and RLE normalized CAGE-derived expression levels of RefSeq protein-coding gene promoters (TSS  $\pm 500$  bp).

To visualize the complexity and specialization of facets according to usage and specificity score of enhancers and genes, we counted the frequency of facet-used enhancers (significantly expressed in at least one contained sample) and gene promoters ( $\geq 1$  TPM in at least one sample) with a specificity score in any of 20 bins distributed between 0 and 1. The number of robustly expressed enhancers and genes per sample were normalized to enhancers and genes per million mapped tags, using the total number of mapped CAGE tags in each sample, and further log-transformed. The counts per million mapped tags were visualized in box plots split by facet (only facets with more than one contained sample were considered).

**Motif analysis on differentially specific enhancer sets.** To identify and compare motif signatures characterizing facet-specific enhancers (permissive set) we applied *de novo* motif analyses. Motif enrichment was analysed using HOMER. Enhancer regions (400 bp) were compared to  $\sim 50,000$  randomly selected genomic fragments of the same region size, as described above. Twenty-five motifs were searched for a range of motif lengths (7–14 bp) resulting in a set of 200 *de novo* motifs per set, which was further filtered to remove redundant motifs. In parallel, we also used HOMER to calculate the enrichment of ChIP-Seq derived motifs. Motif collections including search parameters for all facets are deposited in the web database at <http://enhancer.binf.ku.dk>. Known transcription factor motifs were used to compare motif enrichment between facets.

**Hierarchical clustering of samples.** Tissue and primary cell samples mapped to ontology facets were clustered by complete linkage agglomerative hierarchical clustering based on Jensen–Shannon divergence<sup>39</sup>. In detail, expression values for all enhancers in the permissive set were normalized to sum to 1 for each sample and the square root (proper distance metric) of all pair wise Jensen–Shannon divergences between samples was calculated. Manually selected clades of samples were analysed for differential expression in a similar way as was done for facets (see above). In summary, differentially expressed enhancers (robust set) were identified by Kruskal–Wallis rank sum tests (Benjamini–Hochberg FDR < 0.05) and subsequent NDWD post-hoc tests were performed to find all significant pair-wise differences (Bonferroni single-step adjusted  $P < 0.05$ ) between clades.

**Hierarchical clustering of enhancers.** We used matrices describing each enhancer expression in TPMs for each facet (primary cell facets and tissue facets were clustered independently) and clustered these by complete linkage agglomerative hierarchical clustering using Euclidean distances, as implemented in the gputools R package<sup>62</sup>, and ran these in parallel on a GTX960 Nvidia GPU. Due to limited memory in the GPU, we reduced the matrices to enhancers with total expression > 2.5 TPM in the primary cell set and > 0.6 TPM in the tissue/organ set, resulting in sets of roughly 22,500 enhancers each. To make sure these results were stable, we also explored normalization using fold change versus background in each facet instead of TPM normalization, which resulted in very similar results (data not shown).

We then used the cutree method to select 5 sub-clusters in each tree, starting from the root. Enhancers in each set were then extended  $\pm 300$  nucleotides from their midpoints, and CpG islands and observed/expected CpG ratios were calculated. The resulting sub-clusters broke up enhancers into 201 and 247 ubiquitous enhancers (u-enhancers) defined by cell type and tissue facets, respectively, (these sets intersect by 106 enhancers) and non-ubiquitous enhancers. To summarize the features of u-enhancers in terms of expression width and variance, identified in a single plot, we used those enhancers falling into u-enhancer group from the tissue clustering. We then plotted the mean TPM over all tissue facets, as well as the coefficient of variation (expression variance over all tissue facets scaled by

mean expression). Then we repeated this for the remaining enhancers (non-u-enhancers).

**Zebrafish reporter transgenesis experiments.** We selected enhancers for validation based on human–zebrafish conservation (>70% sequence identity over 100 nucleotides, hg19 vs DanRer7) to take into account the large evolutionary separation between the two species, and selected enhancers that were only expressed in a subset of tissues/cells. We did not take epigenetic data (ChIP/DHS etc.) into consideration. We also selected three negative control regions, chosen randomly from the human genome with the following constraints: low conservation with zebrafish and no other enhancer-selective feature, that is, no DNase hypersensitivity, no H3K4me1 or H3K27ac signals and CAGE signal only at noise levels.

Selected human enhancers (CRE1-5) were amplified from human genomic DNA using primers (Supplementary Table 9). PCR products were purified using NucleoSpin Gel and PCR Clean-up Kit (Macherey Nagel) and were digested using appropriate enzymes (listed in Supplementary Table 9). Human enhancers were cloned into EcoRV/SpeI or HindIII/EcoRI sites of pDB896 vector (gift from D. Balciunas) upstream of zebrafish *gata2* promoter<sup>63,64</sup> and *YFP* reporter gene. Plasmid DNA was purified using NucleoBond Xtra Midi Kit (Macherey Nagel) and quality checked by sequencing before injections.

Zebrafish stocks (*Danio rerio*) were kept and used according to Home Office regulations (UK) at the University of Birmingham. For these experiments wild-type fish (AB\* strain) were used. Adults were crossed pairwise and eggs were collected 10–15 min after fertilization. Microinjection solutions contained 30 ng  $\mu\text{l}^{-1}$  of plasmid DNA, 0.2% of phenol red (Sigma) and 15 ng  $\mu\text{l}^{-1}$  of Tol2 mRNA transcribed *in vitro* from pCS2:Tol2 plasmid using mMESSAGE machine SP6 Kit (Ambion). Injections were performed through the chorion and into the cytoplasm of zygotes using an analogue pressure-controlled microinjector (Tritech Research). More than 200 eggs were injected per construct and experiments were replicated at least three times. Embryos were kept according to ref. 65 in E3 Medium containing 50 ng  $\text{ml}^{-1}$  of gentamicin (Fisher Scientific) and 0.03% phenylthiourea (PTU, Sigma) in an incubator at 28.5 °C.

Injected embryos were screened during the first 5 days post-fertilization using a Nikon SMZ1500 fluorescence stereomicroscope. Specific expression patterns were documented at 48 hpf and levels of expression were quantified by counting the number of embryos showing enhancer-specific expression. To control for overall background activity from the construct (that is, promoter, backbone) an empty pDB896 vector containing *gata2* zebrafish promoter linked to the reporter gene but lacking an enhancer sequence was used. Any tissue-specific enrichment shown by enhancer-containing vectors over the activity shown by the empty control vector was considered enhancer-specific. Additionally, three negative regions were also cloned to check the specificity of the enhancer selection process. These regions were chosen randomly from the human genome to have low conservation with zebrafish and no other enhancer-selective feature, that is, no DNase I hypersensitivity, no H3K4me1 or H3K27ac signals and CAGE signal only at noise levels. In parallel, 5 selected human enhancers were also analysed. See Supplementary Table 9 for a summary of zebrafish validations, including expression patterns, signal strengths and primers.

**Analysis of cohesin data.** We used MCF7 cell ChIP experiments with antibodies targeting STAG1 and RAD21 proteins, downloaded from the Short Read archive (accession nos ERR011980, ERR011982). These were mapped using Bowtie<sup>50</sup> with standard settings but discarding non-unique hits, and peak-called using MACS<sup>53</sup> with default settings. We then used the intersection between peak sets as proxy binding sites for the cohesin complex.

**Linking TSSs and enhancers by expression correlations.** We identified all intrachromosomal enhancer–promoter pairs (470,315 cases, permissive set of enhancers and unique locations of RefSeq protein-coding gene transcript TSSs  $\pm$  500 bp) within 500 kb, in which the TSS was expressed >1 TPM in at least one sample, and performed Pearson correlation tests between the expression of such pairs: 64% of enhancers had at least one significant association (Benjamini–Hochberg FDR  $\leq$  10<sup>−5</sup>) within that distance. On average, a TSS was associated with 4.9 enhancers and an enhancer with 2.4 TSSs.

Next, we identified which predicted associations were supported by ENCODE ChIA-PET (via RNAPII (MMS-126R)) interaction data<sup>21</sup> from four ENCODE cell lines (HCT-116, HeLa-S3, K562, MCF-7) by requiring an overlap of both enhancer and promoter in both (and different) sites of a ChIA-PET interaction pair. An association was considered supported if it overlapped in this way with any cell line replicate of interactions.

For comparison, the fraction of 1,672,958 published<sup>10</sup> predicted enhancer–promoter associations derived from DNase data supported by ENCODE ChIA-PET interaction data was calculated.

**Analysis of genomic clusters of densely positioned enhancers.** By pairwise distance calculations between CAGE enhancers, we identified clusters of densely positioned enhancers (mid points separated by <2 kb) in the genome. 815 regions

of length  $\geq$  2 kb containing >2 enhancers were identified. Of these, 198 regions contained enhancers whose average pairwise expression correlation (Pearson's  $r$ ) were  $\geq$  0.75. The expression of associated RefSeq genes (see 'Linking TSSs and enhancers by expression correlations') as well as their enrichment of gene ontology biological process terms (via the DAVID tool<sup>66</sup>) were compared to that of genes associated with non-clustered enhancers.

**Inferring regulatory architectures by multiple linear regression.** Multiple linear regression was performed for all 25,144 expressed (max TPM >1) RefSeq TSSs with at least ten FANTOM5 CAGE-defined enhancers within 500 kb. Enhancers were ranked by proximity to the TSS and the expression values across all samples of the ten closest were used as predictor variables in a model with the TSS expression as response variable. The expression data of enhancers and TSSs were centred and rescaled. 2,206 TSS models, considering in total 11,386 enhancers, with  $R^2 \geq$  0.5 were considered for further analyses. We also fitted a simple linear regression model using each enhancer as predictor variable on their own, in order to compare the predictive power of a single enhancer to the power of using all ten. We defined a new measure of 'proportional contribution' to the variance explained as the ratio between simple linear regression  $r^2$  and multiple linear regression  $R^2$ , for each enhancer among the ten considered for each TSS. This measure yielded highly similar ranking results of enhancers as the  $R^2$  contribution averaged over orderings among regressors<sup>67,68</sup> and  $R^2$  decorrelation decomposition<sup>67,69</sup> (data not shown), implemented in the 'relaimpo' R package<sup>37,69</sup> (lmg and car methods, respectively). We used ranking of enhancers according to proportional contribution and within-model enhancer–enhancer correlations to identify TSSs with different enhancer architectures. Redundant enhancers were identified for TSSs that had enhancers that were, by proportional contribution, ranked second and onwards with at least some proportional contribution (> 0.2) and high correlation (Pearson's  $r >$  0.7) with any other of the nine enhancers in the model. Patterning architectures were considered for enhancers in non-redundant models that were, by proportional contribution, ranked second and onwards with at least some proportional contribution (> 0.2) and low correlation (Pearson's  $r <$  0.3) with all other of the nine enhancers in the model.

Penalized lasso-based regression was used to reduce the number of enhancers in the models. The optimal models were selected using 100-fold cross validation and the largest value of lambda such that the mean squared error was within one standard error of the minimum, using the R package glmnet<sup>29,37</sup>

**SNP analysis.** The NIH NHGRI catalogue of published genome-wide association studies<sup>29</sup> (GWAS catalogue, downloaded 7 May 2012) contained 7,899 SNP-disease/trait associations. We extended this set to 190,356 autosomal associations by propagating disease/trait associations to proxy SNPs using the SNAP proxy search tool<sup>70</sup> (<http://www.broadinstitute.org/mpg/snap/>) based on linkage disequilibrium ( $r^2 >$  0.8) between SNPs (within 250 kb) in any of the three populations in the 1000 genomes project pilot<sup>71</sup> data. The 1000 Genome data coordinates were in hg18 coordinates and were mapped to hg19 using the UCSC liftOver tool<sup>72</sup>.

For robust enhancers (centre  $\pm$  200 bp), promoters (unique locations of RefSeq protein-coding gene transcript TSSs  $\pm$  200 bp), exons (unique locations of RefSeq protein-coding gene transcript inner exons), and random regions (described above), we calculated the number of overlapping and non-overlapping GWAS SNPs associated with each disease/trait in the extended GWAS catalogue. Non-associated SNPs were extracted from the NCBI single nucleotide polymorphism database (dbSNP, build 135). For each genomic feature and disease/trait with an odds ratio > 1, we tested whether the observed overlap was significantly greater than expected (Fisher's exact test  $P <$  0.01). Only diseases/traits with more than three SNPs overlapping were tested. The same analysis was repeated for each set of significantly expressed enhancers associated with each facet. For ease of visualization and interpretation, only odds ratios for which the filtering criteria on both significance and overlap number were met are shown. Lists of enhancer-overlapped GWAS SNPs are in S16.

**Statistical tests, visualization and tools used.** Statistical tests were done in the R environment (<http://www.R-project.org>). Graphs were made using lattice, ggplot2 and gplots R packages. Cluster trees were generated by the APE<sup>73</sup> R package and visualized using the FigTree software (<http://tree.bio.ed.ac.uk/software/figtree/>). Intersections of and distances between various genomic features were calculated using BEDTools<sup>74</sup>.

39. Kanamori-Katayama, M. *et al.* Unamplified cap analysis of gene expression on a single-molecule sequencer. *Genome Res.* **21**, 1150–1159 (2011).
40. Khalil, A. M. *et al.* Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. *Proc. Natl Acad. Sci. USA* **106**, 11667–11672 (2009).
41. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010).
42. Hoffman, M. M. *et al.* Unsupervised pattern discovery in human chromatin structure through genomic segmentation. *Nature Methods* **9**, 473–476 (2012).

43. Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and characterization. *Nature Methods* **9**, 215–216 (2012).
44. Heintzman, N. D. *et al.* Histone modifications at human enhancers reflect global cell-type-specific gene expression. *Nature* **459**, 108–112 (2009).
45. Marshall, O. J. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. *Bioinformatics* **20**, 2471–2472 (2004).
46. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* **25**, 1105–1111 (2009).
47. Trapnell, C. *et al.* Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nature Biotechnol.* **28**, 511–515 (2010).
48. Preker, P. *et al.* RNA exosome depletion reveals transcription upstream of active human promoters. *Science* **322**, 1851–1854 (2008).
49. Takahashi, H., Lassmann, T., Murata, M. & Carninci, P. 5' end-centered expression profiling using cap-analysis gene expression and next-generation sequencing. *Nature Protocols* **7**, 542–561 (2012).
50. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10**, R25 (2009).
51. Carninci, P. *et al.* Genome-wide analysis of mammalian promoter architecture and evolution. *Nature Genet.* **38**, 626–635 (2006).
52. Pham, T. H. *et al.* Dynamic epigenetic enhancer signatures reveal key transcription factors associated with monocytic differentiation states. *Blood* **119**, e161–e171 (2012).
53. Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137 (2008).
54. Schmidl, C. *et al.* Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. *Genome Res.* **19**, 1165–1174 (2009).
55. Klug, M. & Rehli, M. Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. *Epigenetics* **1**, 127–130 (2006).
56. Rehli, M. *et al.* PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human Toll-like receptor 4 gene. *J. Biol. Chem.* **275**, 9773–9781 (2000).
57. Li, L. C. & Dahiya, R. MethPrimer: designing primers for methylation PCRs. *Bioinformatics* **18**, 1427–1431 (2002).
58. Ehrich, M. *et al.* Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. *Proc. Natl Acad. Sci. USA* **102**, 15785–15790 (2005).
59. Lin, J. Divergence measures based on the Shannon entropy. *IEEE Trans. Inf. Theory* **37**, 145–151 (1991).
60. Hollander, M. & Wolfe, D. A. *Nonparametric Statistical Methods* (Wiley-Interscience, 1999).
61. Hothorn, T., Hornik, K., Van De Wiel, M. A. & Zeileis, A. A Lego system for conditional inference. *Am. Stat.* **60**, 257–263 (2006).
62. Buckner, J. *et al.* The gputools package enables GPU computing in R. *Bioinformatics* **26**, 134–135 (2010).
63. Ellingsen, S. *et al.* Large-scale enhancer detection in the zebrafish genome. *Development* **132**, 3799–3811 (2005).
64. Meng, A., Tang, H., Ong, B. A., Farrell, M. J. & Lin, S. Promoter analysis in living zebrafish embryos identifies a cis-acting motif required for neuronal expression of GATA-2. *Proc. Natl Acad. Sci. USA* **94**, 6267–6272 (1997).
65. Westerfield, M. *The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio)*. (Univ. Oregon Press, 1995).
66. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature Protocols* **4**, 44–57 (2008).
67. Zuber, V. & Strimmer, K. High-dimensional regression and variable selection using CAR scores. *Stat. Appl. Genet. Mol. Biol.* **10**, 1–27 (2011).
68. Chevan, A. & Sutherland, M. Hierarchical partitioning. *Am. Stat.* **45**, 90–96 (1991).
69. Groemping, U. Relative importance for linear regression in R: the package relaimpo. *J. Stat. Softw.* **17**, 1–27 (2006).
70. Johnson, A. D. *et al.* SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. *Bioinformatics* **24**, 2938–2939 (2008).
71. The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061–1073 (2010).
72. Rhead, B. *et al.* The UCSC Genome Browser database: update 2010. *Nucleic Acids Res.* **38**, D613–D619 (2010).
73. Paradis, E., Claude, J. & Strimmer, K. APE: analyses of phylogenetics and evolution in R language. *Bioinformatics* **20**, 289–290 (2004).
74. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).